Editorial
The effect of smoking and TP53 mutations on molecular-targeted therapy in lung adenocarcinoma patients
Abstract
The treatment of non-small cell lung cancer (NSCLC) reached a major turning point with the discovery of gefitinib as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and the identification of EGFR mutations in 2004 (1).
